Navigation Links
Bronchitol Cystic Fibrosis Dose Trial Results Positive
Date:8/11/2008

more, baseline FEV1 of between 40%

and 80% of the predicted normal value or a

decline in FEV1 of 20% or more in the last 12

months for those >80% predicted

Study population Median age: 16 yrs, mean FEV1: 63% predicted

Trial Location Canada and Argentina

Commercial partners None

Primary end points:

Change in FEV1 8.6% increase (139 mls) on 400 mg Bronchitol.

-1.6% on 40 mg (p=0.0006). 4.6% on 240 mg,

3.7% on 120 mg

Change in FVC 7.9% increase in FVC on 400 mg vs -0.6% on 40 mg

(p=0.0004). 3.9% on 240 mg, 1.5% on 120 mg

Secondary end points:

Other lung function 11.9% increase in MMEF on 400 mg (vs -0.3% on 40

measures; mg, change did not reach significance)

CF Questionnaire Improved 6.3 points on 400 mg vs -0.2 on 40 mg

Safety/adverse events No serious adverse events on 400 mg Bronchitol

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or th
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmaxis Long-Term Safety Study of Bronchitol Completes
2. Pharmaxis Establishes Named Patient Program for Bronchitol
3. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
4. Promising Cystic Fibrosis Compound on Track for Development
5. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
6. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
7. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
8. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
9. Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting
10. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
11. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... FRANCISCO , July 2, 2015  The Green ... ), the world,s first HIPAA compliant mobile app that ... of farm-to-table fresh medical marijuana, announced today that their ... Unlike Eaze, Meadow and more than half a ... the last year, Loud Cannabis is unique in that ...
(Date:7/2/2015)... DURHAM, N.C. , July 2, 2015 ... of assets related to the ion channel biology platform ... previously been obtained as part of Pfizer,s 2011 acquisition ... Pfizer,s rights to the "Icagen" name and trademark.  XRPro ... comprehensive services for ion channel and transporter drug discovery, ...
(Date:7/2/2015)... , 2. Juli 2015 BGI gab ... in Hongkong vom American College of Pathologists ... ist das erste klinische Next-Generation-Sequencing Labor, das ... CAP-Zertifkat erhält und somit die höchsten Standards ... bestehenden US FDA - 21 CFR Part ...
Breaking Medicine Technology:New Cannabis Delivery App Gets Product to Patient in Under 7 Minutes 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2
... 2011 Henry Schein, Inc., (NASDAQ: ... services to office-based practitioners, announced today that Steven ... will present at the Credit Suisse 2011 Healthcare Conference on ... Biltmore Hotel in Phoenix. Henry Schein,s presentation ...
... -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... the development and sale of patented biopharmaceutical medicine, ... active pharmaceutical ingredients (API) announced that following the ... (JCM) has passed the internal quality assessment for ...
Cached Medicine Technology:Henry Schein to Present at Credit Suisse 2011 Healthcare Conference 2JCM Passes Internal Quality Assessment for Azithromycin API Production 2JCM Passes Internal Quality Assessment for Azithromycin API Production 3
(Date:7/3/2015)... ... ... " Selfie on a Stick ” was featured on NewsWatch as part ... to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the ... , Almost every smartphone has an incredibly powerful camera built into it. And when ...
(Date:7/3/2015)... ... , ... Every year, One-to-1 Fitness and the Red Deer Fit Body ... Deer community with free fitness training and indoor fitness boot camp classes for 24 ... raised thousands of charity dollars and ended with a $10,000 donation to the Jumpstart ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to ... the first sweetFrog store located in Mississippi. The premium frozen yogurt chain was listed ... The store, located at 104 Railroad Avenue, New Albany, MS 38652, will have a ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce ... 19th sweetFrog store located in the Lone Star State. The premium frozen yogurt chain ... 2014. , The store, which opened July 1 at Duke’s Travel Plaza, is located ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... Donna Edwards (D-Md.) for her introduction of the Stop Overdose Stat (S.O.S.) Act ... by Senator Jack Reed (D-R.I.), this Act seeks to decrease drug overdose – ...
Breaking Medicine News(10 mins):Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:sweetfrog Opens First Location in Mississippi 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3
... ... for the quarter ending April 30, 2009. With consistent growth and increased orders, ... ... -- Clearly Contacts released their second quarter unaudited financial results today, for the ...
... ... Dr Jav Nazemi - CEO of Igennus, manufacturer of purified omega-3 fish oil ... his business and the omega-3 EPA formula, Vegepa, which has since helped thousands ... to the Children,s Heart Federation, in order to help support the lives of ...
... On Friday the 29th of ... of Merit by the Ameican Otologic Society. The American Otological (Ear) Society was founded ... 1949. , ... On Friday the 29th of May in Phoenix, Arizona, Dr. William H. Lippy from Warren, Ohio ...
... ... Sleep Medicine in Seattle on June 5, 2009 on the subject of educating the public about ... ... meeting of the American Academy of Dental Sleep Medicine in Seattle on June 5, 2009 on ...
... time a mechanism by which nanoparticles ,cause lung damage and ... ,process involved, taking a step toward addressing the growing concerns ... science of the extremely tiny (one nanometre is one-billionth of ... annual market of around ,one trillion US dollars by 2015. ...
... Calif., June 10 IPC The Hospitalist Company, Inc. (Nasdaq: ... today that management is scheduled to present at the Jefferies 3rd ... York City. Adam Singer, M.D., Chairman and CEO, and Jeff ... IPC,s presentation will take place at 3:15 P.M. Eastern time on ...
Cached Medicine News:Health News:Clearly Contacts Announces Another Quarter Of Growth In The Economic Downturn 2Health News:Clearly Contacts Announces Another Quarter Of Growth In The Economic Downturn 3Health News:Omega-3 EPA: Treatment for a Heart Condition 2Health News:Omega-3 EPA: Treatment for a Heart Condition 3Health News:Omega-3 EPA: Treatment for a Heart Condition 4Health News:Omega-3 EPA: Treatment for a Heart Condition 5Health News:Omega-3 EPA: Treatment for a Heart Condition 6Health News:American Otological Society 2009 Recipient For the "Award of Merit" Goes to Dr. William H. Lippy of Warren, Ohio 2Health News:Founder of Snoring Isn't Sexy, LLC Addresses Annual Meeting of the American Academy of Dental Sleep Medicine 2Health News:Scientists advance safety of nanotechnology 2Health News:Scientists advance safety of nanotechnology 3Health News:IPC The Hospitalist Company, Inc. to Present at Jefferies 3rd Annual Healthcare Conference 2
... system utilizes a hot air drying device for ... a clear cellophane support for easy viewing. The ... flat assembly surface for the drying frame. The ... once. This 115 V, 60 Hz system includes ...
... The PRO6000 power supply ... Thermo's power supply product offering. ... proteomic and genomic electrophoresis. This ... to proteomic applications such as ...
The 570-90 is capable of producing up to 500 volts or 2,500 milliamps. It is an excellent choice for running all types of electroblotting applications. Also ideal for PAGE, SDS-PAGE, and DNA or RNA s...
... From simple techniques such as submarine ... Multiple Step IEF, the Series 90 Programmable ... ,The Series 90 Programmable Power Supplies are ... 4000 or 6000V., All models operate in ...
Medicine Products: